Vaxcyte reports Phase 1/2 adult data showing VAX-31 met noninferiority to Prevnar 20 and achieved ~95% IPD coverage

Reuters

Mar 19

Vaxcyte reports Phase 1/2 adult data showing VAX-31 met noninferiority to Prevnar 20 and achieved ~95% IPD coverage

Vaxcyte reported that results from a Phase 1/2 adult study of its 31-valent pneumococcal conjugate vaccine candidate VAX-31 were published in The Lancet Infectious Diseases. In adults aged 50 and older, VAX-31 was evaluated for safety, tolerability, and immunogenicity versus Prevnar 20, and it showed robust opsonophagocytic activity and IgG responses across 31 serotypes. Vaxcyte said the VAX-31 High Dose met noninferiority criteria for 20 serotypes shared with Prevnar 20 and met superiority criteria for 11 additional serotypes not included in Prevnar 20. Based on these results, the company advanced VAX-31 High Dose into its OPUS Phase 3 adult program, with topline data from the OPUS-1 pivotal noninferiority trial expected in Q4 2026. The Phase 3 program includes head-to-head comparisons versus Prevnar 20 and Capvaxive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603181934PRIMZONEFULLFEED9674982) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620572296"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620572296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620572296?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 07:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620572296","market":"nz","top_or_hot":-1,"title":"Vaxcyte reports Phase 1/2 adult data showing VAX-31 met noninferiority to Prevnar 20 and achieved ~95% IPD coverage","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte reports Phase 1/2 adult data showing VAX-31 met noninferiority to Prevnar 20 and achieved ~95% IPD coverage\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxcyte reported that results from a Phase 1/2 adult study of its 31-valent pneumococcal conjugate vaccine candidate VAX-31 were published in The Lancet Infectious Diseases. In adults aged 50 and older, VAX-31 was evaluated for safety, tolerability, and immunogenicity versus Prevnar 20, and it showed robust opsonophagocytic activity and IgG responses across 31 serotypes. Vaxcyte said the VAX-31 High Dose met noninferiority criteria for 20 serotypes shared with Prevnar 20 and met superiority criteria for 11 additional serotypes not included in Prevnar 20. Based on these results, the company advanced VAX-31 High Dose into its OPUS Phase 3 adult program, with topline data from the OPUS-1 pivotal noninferiority trial expected in Q4 2026. The Phase 3 program includes head-to-head comparisons versus Prevnar 20 and Capvaxive.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603181934PRIMZONEFULLFEED9674982) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte reports Phase 1/2 adult data showing VAX-31 met noninferiority to Prevnar 20 and achieved ~95% IPD coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte reports Phase 1/2 adult data showing VAX-31 met noninferiority to Prevnar 20 and achieved ~95% IPD coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 07:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte reports Phase 1/2 adult data showing VAX-31 met noninferiority to Prevnar 20 and achieved ~95% IPD coverage\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxcyte reported that results from a Phase 1/2 adult study of its 31-valent pneumococcal conjugate vaccine candidate VAX-31 were published in The Lancet Infectious Diseases. In adults aged 50 and older, VAX-31 was evaluated for safety, tolerability, and immunogenicity versus Prevnar 20, and it showed robust opsonophagocytic activity and IgG responses across 31 serotypes. Vaxcyte said the VAX-31 High Dose met noninferiority criteria for 20 serotypes shared with Prevnar 20 and met superiority criteria for 11 additional serotypes not included in Prevnar 20. Based on these results, the company advanced VAX-31 High Dose into its OPUS Phase 3 adult program, with topline data from the OPUS-1 pivotal noninferiority trial expected in Q4 2026. The Phase 3 program includes head-to-head comparisons versus Prevnar 20 and Capvaxive.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603181934PRIMZONEFULLFEED9674982) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PCVX","symbol_name":"Vaxcyte, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL99Fmtv:1","article_id":"2620572296","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620572296","pubTimestamp":1773876869,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vaxcyte reported that results from a Phase 1/2 adult study of its 31-valent pneumococcal conjugate vaccine candidate VAX-31 were published in The Lancet Infectious Diseases. In adults aged 50 and older, VAX-31 was evaluated for safety, tolerability, and immunogenicity versus Prevnar 20, and it showed robust opsonophagocytic activity and IgG responses across 31 serotypes. Vaxcyte said the VAX-31 High Dose met noninferiority criteria for 20 serotypes shared with Prevnar 20 and met superiority criteria for 11 additional serotypes not included in Prevnar 20. Based on these results, the company advanced VAX-31 High Dose into its OPUS Phase 3 adult program, with topline data from the OPUS-1 pivotal noninferiority trial expected in Q4 2026. The Phase 3 program includes head-to-head comparisons versus Prevnar 20 and Capvaxive.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PCVX":"Vaxcyte, Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Vaxcyte报告1/2期成人数据显示VAX-31符合Prevnar 20的非劣效性，并实现了约95%的IPD覆盖率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PCVX":0.9},"content_text":"Vaxcyte reports Phase 1/2 adult data showing VAX-31 met noninferiority to Prevnar 20 and achieved ~95% IPD coverage\n    \n\n        Vaxcyte reported that results from a Phase 1/2 adult study of its 31-valent pneumococcal conjugate vaccine candidate VAX-31 were published in The Lancet Infectious Diseases. In adults aged 50 and older, VAX-31 was evaluated for safety, tolerability, and immunogenicity versus Prevnar 20, and it showed robust opsonophagocytic activity and IgG responses across 31 serotypes. Vaxcyte said the VAX-31 High Dose met noninferiority criteria for 20 serotypes shared with Prevnar 20 and met superiority criteria for 11 additional serotypes not included in Prevnar 20. Based on these results, the company advanced VAX-31 High Dose into its OPUS Phase 3 adult program, with topline data from the OPUS-1 pivotal noninferiority trial expected in Q4 2026. The Phase 3 program includes head-to-head comparisons versus Prevnar 20 and Capvaxive.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603181934PRIMZONEFULLFEED9674982) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}